Information  X 
Enter a valid email address

Valirx PLC Ord 0.1P (VAL)

Related News

08-Apr-2014 07:42 AM

ValiRx in risk-sharing JV with Tangent Reprofiling Ltd

ValiRx Plc, the life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, has established ValiSeek Limited, a risk-sharing JV company with Tangent Reprofiling Limited. ValiSeek has acquired a worldwide exclusi
19-Mar-2014 07:42 AM

ValiRx widens FY pretax loss to £2.9m

ValiRx widened its FY pretax loss to £2.9m, from £2.3m. Revenue was £0.12m, from £0.22m. Research, development and administrative expenses accounted for most of the loss. "We now have a secure funding platform upon which we can consolidate the f
05-Sep-2013 07:38 AM

ValiRx H1 pretax loss widens to £1.5m due to R&D

ValiRx widened its first-half pretax loss to £1.5 million, from a loss of £1.1 million, reflecting a hike in research and development. R&D expenditure weighed in at £0.9 million, form £0.5 million. "The Company has made some very encouraging pr
15-Apr-2013 02:35 PM

Valirx to present at the London Innovation & Growth Investor Evening on 9th May 2013

Dr Satu Vainikka, Chief Executive Officer of Valirx (VAL)(VAL.L)[LON:VAL] the life science company, will be presenting at the Shares Magazine Innovation & Growth Investor Evening in London on 9th May 2013. The Innovation & Growth Investor Evening will sho
28-Mar-2013 07:57 AM

ValiRx more than doubles FY pretax loss

Life science company ValiRx more than doubled its pretax loss to £2.2 million, from £0.9 million, and said it plans to further advance its pre-clinical development pipeline. Revenue for the year was £0.2 million, from £0.5 million. "Looking to
11-Oct-2012 08:19 AM

ValiRx agrees UK distribution deal with First Health

ValiRx announces that its sales and distribution divisional subsidiary, ValiMedix, has entered into a UK distribution agreement with First Health Products Limited for the distribution and sale of ValiRx's SELFCheck health screening products in the UK
20-Sep-2012 09:46 AM

ValiRx losses down to increased R&D spend

ValiRx reports that revenues for the half-year were £157,535 (2011: £418,263). Administrative expenses were £709,148 (2011: £417,508)and losses after taxation were £1,088,122 (2011: losses £161,392). In the half-year £540,211 (2011: £152,935) wa
15-May-2012 09:53 AM

Valirx granted new US patent

ValiRx has announced that a method for cancer screening, using specific gene biomarkers in the field of genetics and oncology, has received patent approval by the US patent office. The granting of this latest patent means that ValiRx now has biomarker p
27-Apr-2012 09:19 AM

Revenues rise for ValiRx

ValiRx reports that revenues for the year rose to £455,000 (2010: £177,000). Administrative expenses were £1,513,000 (2010: £663,000). Included in administrative expenses were research and development costs of £421,000 (2010: £120,000). Losses aft
29-Mar-2012 09:10 AM

ValiRx signs agreement with IPC

ValiRx the life science company has concluded a Material Transfer Agreement (MTA) with the Institut Paoli & Calmettes (IPC) in Marseille, France. In the MTA, IPC will conduct translational and developmental studies on ValiRx's lead compound, VAL201
14-Feb-2012 09:29 AM

ValiRx sets up Scientific & Advisory Board

ValiRx, a life science has established a Scientific Advisory Board (SAB) to advise and assist the Company as it looks to further develop its technologies and products in oncology therapeutics and diagnostics. The SAB will be instrumental in the capacity
02-Feb-2012 07:59 AM

New European patent grant for ValiRx

ValiRx, the life science company with a focus on cancer diagnostics, has announced that a cancer screening test biomarker called NAV3, one of the five patent family assets its subsidiary, ValiFinn Oy acquired from Pharmatest Services of Finland, has recen
05-Jan-2012 09:01 AM

ValiRx acquires Pharmatest biomarkers business

ValiRx has acquired from Pharmatest Services Oy of Oulu, Finland, its biomarkers business unit together with 5 families of patents and patent applications and related intellectual property. The consideration is a payment of �?¬75,000 and the allotm
03-Nov-2011 09:19 AM

ValiRx files for new patent

ValiRx files for new patent for additional indication in endometriosis or hormone induced abnormal cell growth in women. At 9:19am: (LON:VAL) share price was +0.06p at 0.58p Story provided by
22-Sep-2011 07:25 AM

Valirx points to strengthened balance sheet

Valirx Plc, the life science company has announced its half-yearly report for the six months ended 30 June 2011, showing revenue for the six months to 30 June 2011 rose to £418,263 (Six months to 30 June 2010: £64,474; year to 31 December 2010: £177,297)
08-Sep-2011 08:01 AM

ValiRx agrees Nordic distribution deal with Medcase

ValiRx Plc, a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, has signed an agreement with Medcase, a Finnish distributor operating across the Nordic region, for the distribution and sale of ValiRx'
10-Jun-2011 08:14 AM

ValiRx transfers patent application

ValiRx , a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, has agreed to vary certain terms of the sale and purchase agreement between Singapore Volition Pte. Limited and the Company in relation to the s
02-Jun-2011 07:21 AM

ValiRX gets new director

ValiRx, the life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, has announced the appointment of Oliver de Giorgio-Miller, as an independent non-executive Director of the company. Aged 60, he has extensive
31-May-2011 07:51 AM

ValiRx sees revenues rise

ValiRx, the life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, has seen revenue for the year increased to £177,297 (2009: £29,326) in its final results. The company pointed to solid progress with pre-clin
07-Mar-2011 12:13 PM

ValiRx says progress slowed by capital constraints

Life science company ValiRx plc said its progress had been slowed by capital constraints. However, an equity issue announced on February 16 had provided the company with the opportunity to accelerate development of its programmes. Chairman Nick Thorn
10-Nov-2010 11:24 AM

ValiRx says extra funds will speed lead drugs development

Cancer-focused life science company ValiRx raised £0.225m gross via a placing with an institutional investor at 0.1875p per share. The company said the funds would enable it to develop its anti-cancer lead drug candidates VAL 101 and VAL 102 more quickly
30-Sep-2010 02:22 PM

ValiRx pre-tax losses fall to £0.3m from £0.7m

Story provided by
23-Sep-2010 09:47 AM

ValiRx sells Belgian business for $1m

Life science company ValiRx has sold its Belgian diagnostic development business ValiBIO to Singapore Volition for $1.0m in cash and shares. ValiRx says it will retain a significant share in the future upside value and revenues of ValiBIO via a consultan
12-Aug-2010 09:24 AM

ValiRx in licensing deal to develop prostate cancer treatment

Life science company ValiRx has signed a licensing agreement with Cancer Research Technology to develop a prostate cancer treatment. ValiRx has acquired global commercial rights to the compound VAL 201. The compound has been shown in models to stop the
15-Jul-2010 08:50 AM

ValiRx smear test starts clinical validation

Cancer treatment specialist, ValiRx reports that its human papilloma virus ("HPV") smear test to detect the onset of cervical cancer in women has now begun clinical sample validation. CEO Dr Satu Vainikka, CEO says: "I am delighted and ver
Top categories

03-Jul-2020 04:50 PM

Broker Forecast - Barclays Capital issues a broker note on Gamma Communications Plc

Barclays Capital today reaffirms its overweight investment rating on Gamma Communications Plc (LON:GAMA) and raised its price target to 1600p (from 15 ...

Company finder
Forthcoming announcements

a d v e r t i s e m e n t